Breast Cancer Liquid Biopsy Market Report 2026

Breast Cancer Liquid Biopsy Market Overview

• Breast Cancer Liquid Biopsy market size has reached to $0.89 billion in 2025 • Expected to grow to $1.75 billion in 2030 at a compound annual growth rate (CAGR) of 14.3% • Growth Driver: Rising Breast Cancer Cases Fuel Demand For Advanced Diagnostics • Market Trend: Advancements In Companion Diagnostics For Personalized Cancer Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Breast Cancer Liquid Biopsy Market?

A breast cancer liquid biopsy is a minimally invasive test that detects and analyzes tumor-derived materials in a patient’s blood or other bodily fluids. It provides valuable insights into the presence, progression, and genetic profile of breast cancer without requiring a traditional tissue biopsy. The main products of breast cancer liquid biopsy are consumables and kits. Breast cancer liquid biopsy consumables refer to the disposable materials, reagents, and kits used during the process of conducting liquid biopsy tests for detecting and analyzing biomarkers associated with breast cancer. The various biomarkers include extracellular vesicles (EVS), cell-free dna (cfDNA), circulating tumor RNA (ctRNA), circulating tumor cells (CTCS), cell-free RNA (cfRNA), and others, and several applications including early detection or screening, diagnosis, and others. The different end users encompass laboratories, hospitals, physician laboratories, reference laboratories, public health laboratories, research institutes, small molecular laboratories, and pathology laboratories.

What Is The Breast Cancer Liquid Biopsy Market Growth Forecast?

The breast cancer liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $1.75 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to precision oncology adoption, AI-based mutation analysis, personalized treatment planning, growth in cfDNA testing, decentralized cancer diagnostics. Major trends in the forecast period include multi-biomarker blood-based testing, non-invasive cancer monitoring, treatment response tracking, early recurrence detection, personalized oncology diagnostics.

Global Breast Cancer Liquid Biopsy Market Segmentation

1) By Product: Consumables, Kits 2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers 3) By Application: Early Detection Or Screening, Diagnosis, Other Applications 4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories Subsegments: 1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes 2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

What Is The Driver Of The Breast Cancer Liquid Biopsy Market?

The increase in breast cancer cases is expected to propel the growth of the breast cancer liquid biopsy market going forward. Breast cancer is a type of cancer that develops in the cells of the breast, typically in the lobules (milk-producing glands) or ducts (pathways that carry milk to the nipple). Breast cancer cases are on the rise due to factors including genetic predisposition, hormonal imbalances, aging population, lifestyle changes, obesity, alcohol consumption, lack of physical activity, exposure to radiation, and environmental pollutants. A breast cancer liquid biopsy is used in treatment to detect circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, helping to monitor the disease in real-time. It aids in assessing treatment response, detecting therapy resistance, and identifying genetic mutations for targeted therapies. For instance, in 2025, according to the American Cancer Society, a US-based nonprofit organization dedicated to cancer research, education, advocacy, and patient support, the number of new breast cancer cases is expected to rise to 319,750 in 2025, up from 313,510 cases in 2024. Therefore, the increase in breast cancer cases is driving the growth of the breast cancer liquid biopsy industry.

Key Players In The Global Breast Cancer Liquid Biopsy Market

Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

Global Breast Cancer Liquid Biopsy Market Trends and Insights

Major companies operating in the breast cancer liquid biopsy market are focusing on developing innovative products, such as companion diagnostics, to enable personalized treatment approaches by identifying patients who benefit from specific therapies. Companion diagnostics utilize liquid biopsy technologies to detect biomarkers such as genetic mutations, circulating tumor DNA (ctDNA), or protein expressions indicative of treatment responsiveness. For instance, in January 2023, Guardant Health Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Menarini Group’s ORSERDU (elacestrant), a treatment for advanced or metastatic breast cancer patients with ESR1 mutations. This approval enables oncologists to use the test for comprehensive genomic profiling, identifying patients who may benefit from the targeted therapy. It marks Guardant Health’s first U.S. Food and Drug Administration (FDA) approval in breast cancer and expands its role in precision oncology.

What Are Latest Mergers And Acquisitions In The Breast Cancer Liquid Biopsy Market?

In January 2024, Guardant Health Inc., a US-based biotechnology company dedicated to conquering cancer through liquid biopsies, partnered with Hikma Pharmaceuticals plc. With this collaboration, Hikma seeks to enhance early cancer detection, monitor recurrence, and optimize treatment selection using Guardant Health’s cutting-edge liquid and tissue biopsy technologies. This partnership strengthens Guardant’s global reach, tackling the growing cancer challenge in the Middle East and North Africa. Hikma Pharmaceuticals plc is a UK-based pharmaceutical company.

Regional Outlook

North America was the largest region in the breast cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Breast Cancer Liquid Biopsy Market?

The breast cancer liquid biopsy market consists of revenues earned by entities by providing services such as early cancer detection, treatment monitoring, minimal residual disease (MRD) detection, recurrence prediction, and genetic mutation analysis for targeted therapy selection. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast cancer liquid biopsy market also includes sales of circulating tumor DNA (ctDNA) assay kits, circulating tumor cell (CTC) detection systems, next-generation sequencing (NGS) panels, PCR-based liquid biopsy tests, blood collection tubes, and consumables and reagents used for non-invasive cancer diagnostics and monitoring. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.